NASDAQ:TNXP - Tonix Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $2.00
  • Forecasted Upside: 229.87 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.61
▼ -0.0197 (-3.15%)

This chart shows the closing price for TNXP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Tonix Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TNXP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TNXP

Analyst Price Target is $2.00
▲ +229.87% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Tonix Pharmaceuticals in the last 3 months. The average price target is $2.00, with a high forecast of $2.00 and a low forecast of $2.00. The average price target represents a 229.87% upside from the last price of $0.61.

This chart shows the closing price for TNXP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Tonix Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/4/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/3/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/30/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/30/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/28/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/27/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/26/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/11/2021Alliance Global PartnersLower Price TargetBuy$4.00 ➝ $2.00High
2/25/2021Alliance Global PartnersBoost Price TargetBuy$3.00 ➝ $4.00High
8/20/2020Alliance Global PartnersBoost Price Target$2.50 ➝ $3.00High
8/30/2019Roth CapitalLower Price TargetBuy$4.00 ➝ $1.30Low
4/18/2019Roth CapitalUpgradeNeutral ➝ Buy$4.00Low
7/27/2018Brookline Capital ManagementDowngradeBuy ➝ HoldLow
7/27/2018B. RileyReiterated RatingBuy ➝ Neutral$80.00 ➝ $80.00High
7/27/2018Roth CapitalReiterated RatingBuy ➝ Neutral$60.00 ➝ $10.00High
6/6/2018B. RileyInitiated CoverageBuy$80.00High
5/1/2018Brookline Capital ManagementReiterated RatingBuyLow
12/1/2017AegisReiterated RatingBuyMedium
8/23/2017Dawson JamesReiterated RatingBuy$90.00Medium
8/22/2017Drexel HamiltonInitiated CoverageBuyHigh
8/18/2017Roth CapitalUpgradeNeutral ➝ Buy$60.00High
6/26/2017AegisInitiated CoverageBuy$100.00High
12/20/2016OppenheimerReiterated RatingHoldN/A
(Data available from 9/27/2016 forward)

News Sentiment Rating

0.46 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
3/1/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/31/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/30/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/29/2021
  • 2 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/29/2021
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
8/28/2021
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/27/2021

Current Sentiment

  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Tonix Pharmaceuticals logo
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in New York, NY.
Read More

Today's Range

Now: $0.61
Low: $0.60
High: $0.62

50 Day Range

MA: $0.71
Low: $0.59
High: $1.05

52 Week Range

Now: $0.61
Low: $0.51
High: $2.12

Volume

8,900,100 shs

Average Volume

20,945,514 shs

Market Capitalization

$216.77 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.32

Frequently Asked Questions

What sell-side analysts currently cover shares of Tonix Pharmaceuticals?

The following sell-side analysts have issued reports on Tonix Pharmaceuticals in the last twelve months: Alliance Global Partners.
View the latest analyst ratings for TNXP.

What is the current price target for Tonix Pharmaceuticals?

1 Wall Street analysts have set twelve-month price targets for Tonix Pharmaceuticals in the last year. Their average twelve-month price target is $2.00, suggesting a possible upside of 229.9%. Alliance Global Partners has the highest price target set, predicting TNXP will reach $2.00 in the next twelve months. Alliance Global Partners has the lowest price target set, forecasting a price of $2.00 for Tonix Pharmaceuticals in the next year.
View the latest price targets for TNXP.

What is the current consensus analyst rating for Tonix Pharmaceuticals?

Tonix Pharmaceuticals currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TNXP will outperform the market and that investors should add to their positions of Tonix Pharmaceuticals.
View the latest ratings for TNXP.

How do I contact Tonix Pharmaceuticals' investor relations team?

Tonix Pharmaceuticals' physical mailing address is 509 MADISON AVENUE SUITE 1608, NEW YORK NY, 10022. The company's listed phone number is (212) 980-9155 and its investor relations email address is [email protected] The official website for Tonix Pharmaceuticals is www.tonixpharma.com.